Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Raw Materials (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Raw Materials for 4 consecutive years, with $5.0 million as the latest value for Q1 2026.

  • For Q1 2026, Raw Materials rose 248.79% year-over-year to $5.0 million; the TTM value through Mar 2026 reached $5.0 million, up 248.79%, while the annual FY2025 figure was $4.1 million, 134.88% up from the prior year.
  • Raw Materials hit $5.0 million in Q1 2026 for Phathom Pharmaceuticals, up from $4.1 million in the prior quarter.
  • Across five years, Raw Materials topped out at $5.0 million in Q1 2026 and bottomed at $111000.0 in Q2 2023.
  • Average Raw Materials over 4 years is $1.6 million, with a median of $1.2 million recorded in 2024.
  • Year-over-year, Raw Materials skyrocketed 1717.12% in 2024 and then tumbled 50.02% in 2025.
  • Phathom Pharmaceuticals' Raw Materials stood at $561000.0 in 2023, then surged by 208.2% to $1.7 million in 2024, then soared by 134.88% to $4.1 million in 2025, then rose by 23.76% to $5.0 million in 2026.
  • According to Business Quant data, Raw Materials over the past three periods came in at $5.0 million, $4.1 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.